BACKGROUND: Trastuzumab-based chemotherapy is the standard first-line treatment for patients with HER2-positive advanced or metastatic gastric cancer (GC). However, evidence on real-world outcomes according to the chemotherapy backbone remains limited. METHODS: A total of 2,399 patients with GC treated with trastuzumab-based chemotherapy were analyzed, 486 patients were treated with trastuzumab/5-fluorouracil/cisplatin (HFP) and 1,913 patients were treated with trastuzumab/capecitabine/cisplatin (HXP). Time to subsequent treatment (TST) and overall survival (OS) were analyzed according to the type of chemotherapy backbone. RESULTS: With a median follow-up of 10.5 months, the median TST was 6.08 months 95% confidence interval (CI) 5.65-6.60 in the HFP group and 8.02 months (95% CI 7.72-8.57) in the HXP group (p < 0.0001). The median OS was 9.89 months (95% CI 8.94-10.87) for the HFP group and 13.27 months (95% CI 12.75-14.00) for the HXP group (p < 0.0001). Specifically, HXP followed by trastuzumab and capecitabine maintenance (HXP-HX) demonstrated the best outcomes with median TST of 13.44 months (95% CI 12.52-15.61) and median OS of 22.18 months (95% CI 20.83-24.44) compared with HXP followed by trastuzumab maintenance (HXP-H) and HXP alone (both p < 0.0001), which were also significant in multivariable analysis. CONCLUSIONS: HXP-HX showed the best survival outcomes for patients with locally advanced unresectable, or metastatic HER2-positive GC based on real-world big data analysis of the ToGA regimen, suggesting that HXP-HX is recommended over HXP-H. In the current immunotherapy era for HER2-positive GC, the potential role of capecitabine maintenance as part of combination strategies should be interpreted cautiously and warrants further investigation.
Kim et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: